REFERENCES
- Chung M., Vashi V., Puente J., Sweeney M., Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol. 1999; 48: 678–687
- Daae L. N., Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press. 1998; 7: 39–45
- Davey M. J. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension. Am. J. Med. 1989; 87: 36S–44S
- De Reijke T. M., Klarskov P. Comparative efficacy of two a1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from to benign prostatic enlargement. BJU Int. 2004; 93: 757–762
- Elliott H. L., Meredith P. A., Reid J. L. Pharmacokinetic overview of doxazosin. Am J. Cardiol. 1987; 59: 78G–81G
- Fawzy A., Vashi V., Chung M., Dias N., Gaffney M. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology. 1999; 53: 329–335
- Fitzpatrick J. M., Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int. 2005; 95: 575–579
- Forray C., Noble S. A. Subtype selective alpha 1-adrenoreceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin. Invest. Drugs 1999; 8: 2073–2094
- Fulton B., Wagstaff A. J., Sorkin E. M. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295–320
- Gwak H. S., Chun I. K. Simplified HPLC method for the determination of prazosin in plasma and its application to single-dose pharmacokinetics. J. Appl. Pharmacol. 2005; 13: 90–94
- Intl. Conf. on Harmonisation Topic Q 2B, Validation of Analytical Procedures: Methodology, Step 4, Consensus Guideline, 1996.
- James S., Chapple C. R., Phillips M. I., Greengrass P. M., Davey M. J., Turner-Warwick R. T., Milroy E. J., Burnstock G. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J. Urol. 1989; 142: 438–444
- Karnes H. T., Shiu G., Shah V. P. Validation of bioanalytical methods. Pharm. Res. 1991; 8: 421–426
- Kaye B., Cussans N. J., Faulkner J. K., Stopher D. A., Reid J. L. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br. J. Clin. Pharmacol. 1986; 21: 19S–25S
- Kirby R. S. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int. 2003; 91: 41–44
- Kirby R., Andersson K. E., Lepor H., Steers W. D. Alpha (1)-adrenoreceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 2000; 3: 76–83
- Lepor H., Kaplan S. A., Klimberg I., Mobley D. F., Fawzy A., Gaffney M., Ice K., Dias N. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J. Urol. 1997; 157: 525–530
- Shapiro E., Hartanto V., Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992; 21: 297–307
- Sripalakit P., Nermhom P., Saraphanchotiwitthaya A. Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 2006; 20: 729–735
- Rubin P. C., Brunton J., Meredith P. Determination of the vasodilator UK 33274 by high-performance liquid chromatography using fluorescence detection. J. Chromatogr. 1980; 221: 193–195